Rockwell Medical Resolves Nasdaq Bid Price Deficiency, Regains Full Compliance
RMTI sits 25% above its 52-week low of $4.885 on elevated volume (2.9× avg).
Summary
Rockwell Medical has regained compliance with Nasdaq's minimum bid price rule, and the exchange has closed the matter. The company is now in full compliance with all listing requirements, removing the delisting threat.
Key Events · Corporate Governance and Compliance · RMTI
-
Nasdaq Compliance Regained
On July 16, 2026, Rockwell Medical received notice that it had regained compliance with the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company's shares maintained a closing bid price of at least $1.00 from July 1 through July 15, 2026.
-
Delisting Risk Removed
Nasdaq has formally closed the compliance matter. Rockwell Medical is now in full compliance with all Nasdaq continued listing requirements, and its stock remains listed on the Nasdaq Capital Market under ticker RMTI.
-
Reverse Split Enabled Compliance
The regained compliance follows the 1-for-10 reverse stock split that became effective July 1, 2026, which was approved by shareholders on June 15 and implemented to address the bid price deficiency.
-
Prior Deficiency Notice Resolved
The company had received a Nasdaq deficiency notice on May 8, 2026, for failing to maintain a $1.00 minimum bid price. The reverse split and subsequent price performance have now cured that deficiency.
Analysis · RMTI · Life Sciences
The overhang from Rockwell Medical's Nasdaq listing deficiency has been lifted. On July 16, the company received notice that it had regained compliance with the minimum $1.00 bid price requirement, and Nasdaq formally closed the matter. This eliminates the immediate delisting risk that had been in play since the deficiency notice in May. The turnaround was driven by the 1-for-10 reverse stock split that took effect July 1, which pushed the share price above the threshold. With the matter now closed, the company is in full compliance with all Nasdaq continued listing requirements, removing a key source of uncertainty.
At the time of this filing, RMTI was trading at $6.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2M. The 52-week trading range was $4.89 to $21.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.